Lymphedema (PDQ®): Supportive care - Health Professional Information [NCI] - Overview
Introduction Lymphedema is swelling that occurs when protein-rich lymph fluid accumulates in the interstitial tissue. This lymph fluid may contain plasma proteins,extravascular blood cells,excess water,and parenchymal products.[ 1 ] Lymphedema is one of the most poorly understood,relatively underestimated,and least researched complications of cancer or its treatment. The Institute of ...
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Harms of Screening Mammography
Mammography screening may be effective in reducing breast cancer mortality in certain populations, but it can pose harm to women who participate. The limitations are best described as false-positives (related to the specificity of the test), overdiagnosis (true-positives that will not become clinically significant), false-negatives (related to the sensitivity of the test), discomfort associated with the test, radiation risk and anxiety.False-Positives Leading to Possible Additional InterventionsThe specificity of mammography (refer to the Breast Cancer Screening Concepts section of this summary for more information) affects the number of additional interventions due to false-positive results. Even though breast cancer is the most common noncutaneous cancer in women, fewer than 5 per 1,000 women actually have the disease when they are screened. Therefore, even with a specificity of 90%, most abnormal mammograms are false-positives. Women with abnormal
Urethral Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Urethral Cancer
Recurrent urethral cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the urethra or in other parts of the body.
PC-SPES (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Human / Clinical Studies
One published randomized cross-over study of patients with androgen-independent (AI) prostate cancer who initially received either 960 mg of PC-SPES 3 times a day or 3 mg of diethylstilbestrol (DES) once a day before crossing over to the other regimen; when disease progression occurred, there were reports of data demonstrating the presence and levels of adulterants in the four lots of PC-SPES used in this trial. The lots were manufactured by BotanicLab (Brea, California). The study was halted and chemical analyses of the lots were performed. The analyses showed that all four lots of PC-SPES contained amounts of DES ranging from 0.1 μg/g to 32.7μg/g, and that one lot contained varying amounts of ethinyl estradiol. The authors concluded that the presence of these adulterants rendered their results inconclusive.Several nonrandomized clinical studies published between 1999 and 2003 described the results of clinical trials conducted before adulterants had been conclusively
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Adrenocortical Carcinoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Adrenocortical Carcinoma
There are several staging systems in use. The American Joint Committee on Cancer (AJCC) staging system  is based on the following assessment:The stage of adrenocortical carcinoma is determined by the size of the primary tumor, the degree of local invasion, and whether it has spread to regional lymph nodes or distant sites. Proper staging should include computed tomography (CT) of the abdomen and chest. Magnetic resonance imaging (MRI) may add specificity to CT evaluation of an adrenal mass. In-phase and out-of-phase T1-weighted imaging may be the most effective noninvasive method to differentiate benign from malignant adrenal masses. MRI may suggest evidence of extracapsular tumor invasion, extension into the vena cava, or metastases. Patency of surrounding vessels can often be demonstrated with gadolinium-enhanced sequences or flip-angle techniques.In addition to the above-mentioned AJCC staging, the European Network for the Study of Adrenal Tumors (ENSAT) staging system
Depression (PDQ®): Supportive care - Health Professional Information [NCI] - Palliative Sedation
The use of palliative sedation for psychosocial and existential symptoms can be particularly controversial. The clinician may face many ethical and clinical questions—questions that are more easily resolved in the case of palliative sedation for pain and physical symptoms than for depression and psychosocial symptoms.For example, the ethical basis for the use of terminal sedation (double effect) is less clearly applicable in the case of psychiatric symptoms. Under the principle of double effect, the intended effect (relieving psychological suffering) would be considered allowable as long as any risks or negative effects (i.e., shortened survival) are unintended by the health care professional. The difficulty arises because the principle only discusses the professional's intention, when it is the patient's intention that can be unclear and potentially problematic. Is the depressed patient who no longer wants to suffer depressive symptoms asking only for that relief, or does the
Fever, Sweats, and Hot Flashes (PDQ®): Supportive care - Patient Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment
Breast Cancer Treatment and Pregnancy (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
Early Stage Breast Cancer (Stage I and Stage II)Treatment of early stage breast cancer (stage I and stage II) may be surgery followed by adjuvant therapy as follows: Modified radical mastectomy.Breast-conserving surgery: Lumpectomy, partial mastectomy or segmental mastectomy.Breast-conserving surgery during pregnancy followed by radiation therapy after the baby is born.Surgery during pregnancy followed by chemotherapy after the first 3 months of pregnancy.Clinical trials of surgery followed by hormone therapy with or without chemotherapy.Late Stage Breast Cancer (Stage III and Stage IV)Treatment of late stage breast cancer (stage III and stage IV) may include the following:Radiation therapy.Chemotherapy.Radiation therapy and chemotherapy should not be given during the first 3 months of pregnancy.